Results 211 to 220 of about 104,289 (264)

Prognostic and Predictive Significance of Selected Gene Mutations in Pancreatic and Intestinal Neuroendocrine Tumors. [PDF]

Int J Mol Sci
Musiałkiewicz J, Budny B, Anioła A, Maciejewski A, Komarnicki P, Maciejewska J, Gut P, Ruchała M.   +7 more
europepmc   +1 more source

Dual-Target Inhibition of CDK5 and PBK in Pituitary Neuroendocrine Tumors: Mechanisms and Therapeutic Potential. [PDF]

Genes (Basel)
Jin J, Yi Z, Wang H, Gong L, Zhang Y, Xie W.   +5 more
europepmc   +1 more source

Functional Status and Postoperative Outcomes After Left Pancreatectomy for Pancreatic Neuroendocrine Tumors: An Exploratory Analysis from the Prospective SPANDISPAN Study. [PDF]

J Clin Med
Ramia JM, Hernández-Roca B, Rubio-García JJ, Aparicio-López D, Busquets J, Secanella L, Peláez N, Alkorta M, de Ariño-Hervás I, Del Mar Achalandabaso M, Toledo E, Rotellar F, Martí-Cruchaga P, Ángel Gómez-Bravo M, Suárez G, Garcés-Albir M, Sabater L, García G, Javier Alcalá F, Asensio E, Pacheco D, Cugat E, Espín F, Galófre M, Sánchez B, Santoyo J, Calvo J, Loinaz C, García-Domingo MI, Sánchez-Cabús S, Martín B, Blanco-Fernández G, Jaén-Torrejimeno I, Domingo C, Payá C, González C, Ruiz S, López-Andújar R, Ballester C, Belén Vico A, Zambudio N, Estévez S, Nogueira-Sixto M, Ignacio Miota J, Conde B, Ángel Suárez M, Roldán de la Rúa J, Blanco A, González M, Elena González P, Reyes B, López-Ben S, Tió B, Mínguez J, Lasa I, Miyar A, Solar L, Burdío F, Ielpo B, Carabias A, Sanz-Muñoz MP, Escartín A, Vela F, Marqués E, Pérez A, Palomares G, Calvo A, Tomás Castell J, Jesús Castro M, Manzanares MDC, Artigues E, Luis Blas J, Díez L, Calero A, Quiñones JE, Rodríguez M, Serradilla-Martín M, Alcázar-López CF, Villodre C.   +78 more
europepmc   +1 more source

Editorial Expression of Concern: The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors. [PDF]

Cell Death Dis
Wong C, Laddha SV, Tang L, Vosburgh E, Levine AJ, Normant E, Sandy P, Harris CR, Chan CS, Xu EY.   +9 more
europepmc   +1 more source

Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors. [PDF]

Clin Cancer Res
Arbesfeld-Qiu JM, Cho JW, Nguyen PTT, Lester NA, Su J, Shiau C, Guo JA, Hoffman H, Caldwell NJ, Muratani S, Galvan M, Proctor JE, Ely ZA, Wang S, Ganci M, Dries R, Hong T, Wo J, Boland G, Fernandez-Del Castillo C, Ferrone CR, Heaphy CM, Zhang ML, Mino-Kenudson M, Hemberg M, Hwang WL.   +25 more
europepmc   +1 more source

¹⁸F-FDOPA PET/CT for neuroendocrine tumors in multiple endocrine neoplasia type 1. [PDF]

Front Endocrinol (Lausanne)
Tepede AA, Lee M, Welch J, Mandl A, Cochran C, Hamimi A, Weinstein LS, Simonds WF, Gharib AM, Millo C, Sadowski SM, Blau JE, Jha S.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification

Modern Pathology, 2021
The classification of adenohypophysial neoplasms as "pituitary neuroendocrine tumors" (PitNETs) was proposed in 2017 to reflect their characteristics as epithelial neuroendocrine neoplasms with a spectrum of clinical behaviors ranging from small indolent lesions to large, locally invasive, unresectable tumors.
Sylvia L. Asa, Ozgur Mete, Michael D. Cusimano, Ian E. McCutcheon, Arie Perry, Shozo Yamada, Hiroshi Nishioka, Olivera Casar-Borota, Silvia Uccella, Stefano La Rosa, Ashley B. Grossman, Shereen Ezzat, null International Pituitary Pathology, Sofia Asioli, Süheyla Uyar Bozkurt, Nil Comunoglu, Giulia Cossu, Peter Earls, Nuperi Gazioglu, Richard A. Hickman, Hidetoshi Ikeda, Emilija Manojlovic-Gacic, Mahmoud Messerer, Buge Öz, Sara Pakbaz, Federico Roncaroli, Wolfgang Saeger, John Turchini, Sema Yarman   +28 more
openaire   +2 more sources

Neuroendocrine Tumors

Gastroenterology Clinics of North America, 2016
Neuroendocrine tumors are increasingly diagnosed, either incidentally as part of screening processes, or for symptoms, which have commonly been mistaken for other disorders initially. The diagnostic workup to characterize tumor behaviour and prognosis focuses on histologic, anatomic, and functional imaging assessments. Several therapeutic options exist
Basuroy, Ron, Srirajaskanthan, Raj, Ramage, John K   +2 more
openaire   +3 more sources

Neuroendocrine tumors of the diffuse neuroendocrine system

Current Opinion in Oncology, 2008
Neuroendocrine tumors (previously referred to as carcinoids) are ill-understood, enigmatic malignancies that, although slow-growing compared with adenocarcinomas, can behave aggressively. In 2004, they comprised 1.25% of all malignancies; their incidence is increasing by approximately 6% per year.
Björn I, Gustafsson, Mark, Kidd, Irvin M, Modlin   +2 more
openaire   +2 more sources

Theragnostic in neuroendocrine tumors

The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022
In the last few decades, the incidence and prevalence of neuroendocrine tumors has been increasing. The theragnostic approach, that allows the diagnosis and treatment of different neoplasms with the same ligand, is a typical nuclear medicine tool. Applied for years, is also pivotal in neuroendocrine tumors (NETs) where it has improved the diagnostic ...
Marini I., Sansovini M., Bongiovanni A., Nicolini S., Grassi I., Ranallo N., Monti M., Iorio V. D. I., Germano L., Caroli P., Sarnelli A., Paganelli G., Severi S.   +12 more
openaire   +2 more sources